Pichichero M E, Pichichero D M
University of Rochester Medical Center, New York, USA.
J Pediatr. 1998 Jan;132(1):137-43. doi: 10.1016/s0022-3476(98)70499-8.
The specificity of pediatrician-diagnosed allergy reactions to penicillin, amoxicillin, and oral cephalosporins, which was based on contemporaneous examination of the patient, was evaluated by an elective skin testing program. Children and adolescents (n = 247) experiencing an adverse reaction to penicillin, amoxicillin, and/or an oral cephalosporin sufficient to lead to the recommendation to avoid further use were enrolled. Skin testing with penicillin G, commercial benzylpenicilloyl phosphate, penicillin minor determinate mixture, ampicillin, cefazolin, cefuroxime, and ceftriaxone was performed according to the suspected drug allergy followed by an oral challenge, repeat testing, and prospective follow-up if no reactions were observed. Overall, 84 (34.0%) of 247 patients had an IgE-type reaction on skin testing or oral challenge. Twenty-seven (32%) of 85 suspected penicillin reactions, 53 (34%) of 156 suspected amoxicillin reactions, and 13 (50%) of 26 suspected cephalosporin reactions were shown to be IgE mediated. Positive skin tests were observed in 20 patients with non-IgE-type clinical adverse reactions, including 15 patients with only a pruritic polymorphous rash. No reactions to oral challenge were severe after negative skin testing. One hundred sixty-three patients received multiple treatment courses with beta-lactam antibiotics after a negative skin testing procedure and three (1.8%) had adverse IgE reactions, all of which were mild. Physician-diagnosed allergic reactions to beta-lactam antibiotics based on patient examination at the time of the reaction is more accurate than patient history alone but still overestimates the rate of possible true allergy in 66% of patients. Elective penicillin, amoxicillin, and cephalosporin skin testing and oral challenge protocols are necessary to identify patients not at risk.
通过一项选择性皮肤试验计划,对基于对患者进行同期检查的儿科医生诊断的青霉素、阿莫西林和口服头孢菌素过敏反应的特异性进行了评估。纳入了247名儿童和青少年,他们对青霉素、阿莫西林和/或口服头孢菌素出现了足以导致建议避免进一步使用的不良反应。根据疑似药物过敏情况,使用青霉素G、商用苄青霉素磷酸酯、青霉素次要决定簇混合物、氨苄西林、头孢唑林、头孢呋辛和头孢曲松进行皮肤试验,随后进行口服激发试验、重复试验,若未观察到反应则进行前瞻性随访。总体而言,247名患者中有84名(34.0%)在皮肤试验或口服激发试验中出现IgE型反应。85例疑似青霉素反应中有27例(32%)、156例疑似阿莫西林反应中有53例(34%)、26例疑似头孢菌素反应中有13例(50%)被证明是IgE介导的。在20例非IgE型临床不良反应患者中观察到阳性皮肤试验结果,其中15例患者仅出现瘙痒性多形性皮疹。皮肤试验阴性后,口服激发试验均未出现严重反应。163例患者在皮肤试验阴性后接受了多个疗程的β-内酰胺类抗生素治疗,其中3例(1.8%)出现了不良IgE反应,均为轻度。基于反应时对患者的检查由医生诊断的β-内酰胺类抗生素过敏反应比仅根据患者病史更为准确,但仍高估了66%患者可能真正过敏的发生率。选择性青霉素、阿莫西林和头孢菌素皮肤试验及口服激发试验方案对于识别无风险患者是必要的。